Is Pfizer (PFE) Cheap As Its Enodia Deal Fuels Oncology Growth Hopes?

Pfizer (PFE) is back in focus after signing a research collaboration and license agreement with Enodia Therapeutics that gives the drugmaker access to Enodia’s Sec61 inhibitor programs for potential oncology and specialty treatments. Pfizer’s agreement with Enodia lands at a time when momentum in the shares has been rebuilding, with a 30 day share price return of 6.56% and a 90 day gain of 22.37%. The 1 year total shareholder return of 29.79% contrasts with a weaker 5 year total shareholder...